Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma

Background: Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim...

Descripción completa

Detalles Bibliográficos
Autores: Basagaña Torrentó, Maria|||0000-0002-5478-5945, Martínez Rivera, Carlos|||0000-0003-1031-2561, Padró-Casas, Clara|||0000-0003-0139-5836, Garcia-Olivé, Ignasi|||0000-0001-7698-5107, Martínez-Colls, Mimar, Navarro, Juan, Pardo, Laura|||0009-0009-9237-0634, Cruz, Paula, Cardona Peitx, Gloria, Carabias, Lídia, Roger, Albert, Abad Capa, Jorge|||0000-0002-8129-7859, Rosell Gratacos, Antoni|||0000-0003-0877-7191
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:304784
Acceso en línea:https://ddd.uab.cat/record/304784
https://dx.doi.org/urn:doi:10.1080/07853890.2024.2317356
Access Level:acceso abierto
Palabra clave:Evere asthma
Biologics
Omalizumab
Benralizumab
Mepolizumab
Retrospective analysis
id ES_2dd9350c0decd48ecbaf4dd569df0ac4
oai_identifier_str oai:ddd.uab.cat:304784
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthmaa long-term retrospective analysisBasagaña Torrentó, Maria|||0000-0002-5478-5945Martínez Rivera, Carlos|||0000-0003-1031-2561Padró-Casas, Clara|||0000-0003-0139-5836Garcia-Olivé, Ignasi|||0000-0001-7698-5107Martínez-Colls, MimarNavarro, JuanPardo, Laura|||0009-0009-9237-0634Cruz, PaulaCardona Peitx, GloriaCarabias, LídiaRoger, AlbertAbad Capa, Jorge|||0000-0002-8129-7859Rosell Gratacos, Antoni|||0000-0003-0877-7191Evere asthmaBiologicsOmalizumabBenralizumabMepolizumabRetrospective analysisBackground: Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim of this study was to describe the clinical features of complete responders versus non-complete responders to long-term treatment with biologics in patients with severe asthma attended in routine daily practice. Methods: Data of a cohort of 90 patients with severe asthma who were treated with biologics (omalizumab, benralizumab, and mepolizumab) for at least 12 months and were followed up to March 2022. Data recorded included clinical characteristics and effectiveness of treatment (exacerbation, Asthma Control Test [ACT] score, lung function, use of maintenance oral corticosteroids [mOCS]), FeNO, and blood eosinophils at baseline, at 12 months, and at the end of follow-up. Complete response is considered if, in addition to not presenting exacerbations or the use of mOCS, the ACT score was.Universitat Autònoma de Barcelona. Departament de Medicina 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/304784https://dx.doi.org/urn:doi:10.1080/07853890.2024.2317356reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3047842026-06-06T12:50:31Z
dc.title.none.fl_str_mv Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
a long-term retrospective analysis
title Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
spellingShingle Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
Basagaña Torrentó, Maria|||0000-0002-5478-5945
Evere asthma
Biologics
Omalizumab
Benralizumab
Mepolizumab
Retrospective analysis
title_short Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
title_full Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
title_fullStr Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
title_full_unstemmed Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
title_sort Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma
dc.creator.none.fl_str_mv Basagaña Torrentó, Maria|||0000-0002-5478-5945
Martínez Rivera, Carlos|||0000-0003-1031-2561
Padró-Casas, Clara|||0000-0003-0139-5836
Garcia-Olivé, Ignasi|||0000-0001-7698-5107
Martínez-Colls, Mimar
Navarro, Juan
Pardo, Laura|||0009-0009-9237-0634
Cruz, Paula
Cardona Peitx, Gloria
Carabias, Lídia
Roger, Albert
Abad Capa, Jorge|||0000-0002-8129-7859
Rosell Gratacos, Antoni|||0000-0003-0877-7191
author Basagaña Torrentó, Maria|||0000-0002-5478-5945
author_facet Basagaña Torrentó, Maria|||0000-0002-5478-5945
Martínez Rivera, Carlos|||0000-0003-1031-2561
Padró-Casas, Clara|||0000-0003-0139-5836
Garcia-Olivé, Ignasi|||0000-0001-7698-5107
Martínez-Colls, Mimar
Navarro, Juan
Pardo, Laura|||0009-0009-9237-0634
Cruz, Paula
Cardona Peitx, Gloria
Carabias, Lídia
Roger, Albert
Abad Capa, Jorge|||0000-0002-8129-7859
Rosell Gratacos, Antoni|||0000-0003-0877-7191
author_role author
author2 Martínez Rivera, Carlos|||0000-0003-1031-2561
Padró-Casas, Clara|||0000-0003-0139-5836
Garcia-Olivé, Ignasi|||0000-0001-7698-5107
Martínez-Colls, Mimar
Navarro, Juan
Pardo, Laura|||0009-0009-9237-0634
Cruz, Paula
Cardona Peitx, Gloria
Carabias, Lídia
Roger, Albert
Abad Capa, Jorge|||0000-0002-8129-7859
Rosell Gratacos, Antoni|||0000-0003-0877-7191
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona. Departament de Medicina
dc.subject.none.fl_str_mv Evere asthma
Biologics
Omalizumab
Benralizumab
Mepolizumab
Retrospective analysis
topic Evere asthma
Biologics
Omalizumab
Benralizumab
Mepolizumab
Retrospective analysis
description Background: Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim of this study was to describe the clinical features of complete responders versus non-complete responders to long-term treatment with biologics in patients with severe asthma attended in routine daily practice. Methods: Data of a cohort of 90 patients with severe asthma who were treated with biologics (omalizumab, benralizumab, and mepolizumab) for at least 12 months and were followed up to March 2022. Data recorded included clinical characteristics and effectiveness of treatment (exacerbation, Asthma Control Test [ACT] score, lung function, use of maintenance oral corticosteroids [mOCS]), FeNO, and blood eosinophils at baseline, at 12 months, and at the end of follow-up. Complete response is considered if, in addition to not presenting exacerbations or the use of mOCS, the ACT score was.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/304784
https://dx.doi.org/urn:doi:10.1080/07853890.2024.2317356
url https://ddd.uab.cat/record/304784
https://dx.doi.org/urn:doi:10.1080/07853890.2024.2317356
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405358575845376
score 15.81155

Similares en LA Referencia